losartan has been researched along with Injuries in 3 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Injuries: Used with anatomic headings, animals, and sports for wounds and injuries. Excludes cell damage, for which pathology is used.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We hypothesized that angiotensin II, a potent vasoconstrictor, is involved in the occurrence of hepatic ischemia after burn and sepsis, and that administration of angiotensin II antagonist DuP753 would ameliorate this process." | 7.70 | Trauma- and sepsis-induced hepatic ischemia and reperfusion injury: role of angiotensin II. ( Herndon, DN; Tadros, T; Traber, DL, 2000) |
| "We hypothesized that angiotensin II, a potent vasoconstrictor, is involved in the occurrence of hepatic ischemia after burn and sepsis, and that administration of angiotensin II antagonist DuP753 would ameliorate this process." | 3.70 | Trauma- and sepsis-induced hepatic ischemia and reperfusion injury: role of angiotensin II. ( Herndon, DN; Tadros, T; Traber, DL, 2000) |
| "Losartan was the only medication that showed significantly lower levels of albuminuria after 1 week (P < 0." | 2.84 | A randomised controlled trial evaluating renal protective effects of selenium with vitamins A, C, E, verapamil, and losartan against extracorporeal shockwave lithotripsy-induced renal injury. ( Awadalla, A; Barakat, TS; El-Ghar, MA; El-Nahas, AR; Elsaadany, MM; Elsawy, EA; Elshal, AM; Ismail, AM; Saleh, HH; Sheir, KZ; Taha, DE; Wafa, EW, 2017) |
| "Losartan or placebo treatment was initiated two days before balloon injury in the SHR aorta." | 1.31 | Losartan-induced apoptosis as a novel mechanism for the prevention of vascular lesion formation after injury. ( deBlois, D; Hamet, P; Lemay, J, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Nahas, AR | 1 |
| Elsaadany, MM | 1 |
| Taha, DE | 1 |
| Elshal, AM | 1 |
| El-Ghar, MA | 1 |
| Ismail, AM | 1 |
| Elsawy, EA | 1 |
| Saleh, HH | 1 |
| Wafa, EW | 1 |
| Awadalla, A | 1 |
| Barakat, TS | 1 |
| Sheir, KZ | 1 |
| Tadros, T | 1 |
| Traber, DL | 1 |
| Herndon, DN | 1 |
| Lemay, J | 1 |
| Hamet, P | 1 |
| deBlois, D | 1 |
1 trial available for losartan and Injuries
| Article | Year |
|---|---|
A randomised controlled trial evaluating renal protective effects of selenium with vitamins A, C, E, verapamil, and losartan against extracorporeal shockwave lithotripsy-induced renal injury.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antioxidants; Ascorbic Acid; Calcium Channel Blocker | 2017 |
2 other studies available for losartan and Injuries
| Article | Year |
|---|---|
Trauma- and sepsis-induced hepatic ischemia and reperfusion injury: role of angiotensin II.
Topics: Analysis of Variance; Angiotensin II; Animals; Burns; Drug Evaluation, Preclinical; Escherichia coli | 2000 |
Losartan-induced apoptosis as a novel mechanism for the prevention of vascular lesion formation after injury.
Topics: Animals; Aorta, Thoracic; Apoptosis; Catheterization; DNA Fragmentation; Endothelium, Vascular; Hype | 2000 |